ARA-290 Peptide Guide: Benefits, Dosage & Research Explained

✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

ARA-290 (also called Cibinetide) is an 11-amino-acid research peptide derived from the helix-B region of erythropoietin (EPO). Unlike full-length EPO, it is being studied because it appears to deliver EPO’s tissue-protective and anti-inflammatory signalling without raising red blood cell counts. Early-phase human research has focused on hard-to-treat conditions such as sarcoidosis-associated small-fibre neuropathy, where conventional options often fall short. This guide explains what ARA-290 is, how it interacts with the innate repair receptor, the benefits and uses explored in studies so far, reported side effects, the dosing context seen in trials, and how it compares with alternatives like BPC-157 and gabapentinoids. Everything here is research-focused and qualifying — ARA-290 is not a licensed medicine.

Medically reviewed by the MedsBase editorial team · Last updated: 24 May 2026 · For research and educational use only.

What Is ARA-290?

Erythropoietin is best known as the hormone that drives red blood cell production. Researchers noticed decades ago that EPO also protects injured tissue and dampens inflammation — but using EPO itself for those goals is risky, because raising red cell mass can thicken blood and increase clotting risk. Cibinetide was designed to separate these two jobs.

By mimicking only the helix-B region of EPO, ARA-290 engages the repair-and-protect pathway while leaving the classic EPO-receptor homodimer largely untouched. In practical research terms, this means scientists can study EPO’s protective signalling without the haematological side effects. That selectivity is the core reason ARA-290 attracted clinical interest, particularly for chronic nerve and inflammatory conditions.

It is worth stating plainly: the peptide remains an investigational compound. It has progressed through early-phase human trials but is not licensed or approved as a treatment in any major jurisdiction.

The naming can confuse newcomers. “ARA-290” is the developmental code, while “Cibinetide” is the international nonproprietary name (INN) assigned later. Both refer to the same 11-amino-acid sequence. You will also see it described as an “EPO-derived helix-B peptide” or a “tissue-protective cytokine” in the literature. These are all the same molecule viewed from different angles — chemical structure, regulatory naming, and functional class.

What makes the compound distinctive is not raw potency but selectivity. Many anti-inflammatory agents work by broadly suppressing immune activity, which can leave a patient vulnerable to infection. The repair-receptor approach is conceptually different: it nudges damaged tissue toward survival and self-repair while leaving healthy immune surveillance largely intact. That theoretical profile is a major reason the molecule keeps reappearing in tissue-protection research programmes.

How Does ARA-290 Work? (The Innate Repair Receptor)

The central concept behind ARA-290 is the innate repair receptor (IRR). This is not the classic EPO receptor. Instead, it is a heteroreceptor that pairs one EPO-receptor subunit with the CD131 beta-common chain — the same beta-common chain shared by several cytokine receptors. The IRR is upregulated on stressed or damaged tissue, which is thought to give ARA-290 a degree of injury-targeting.

When the peptide binds the IRR, downstream signalling promotes cell survival, reduces pro-inflammatory cytokine activity, and supports tissue repair. Because it does not efficiently activate the EPO-receptor homodimer responsible for erythropoiesis, it is not expected to raise haematocrit at the doses studied — a key distinction from EPO itself.

Why does the receptor only appear where it is needed? Under healthy conditions, the EPO-receptor and CD131 subunits sit apart and the IRR is scarce. When tissue is injured or inflamed, local signals drive the two subunits together, assembling the heteroreceptor on the surface of stressed cells. This injury-dependent assembly is the mechanism behind the molecule’s apparent targeting: it concentrates its effect where the repair receptor is expressed, rather than acting uniformly across every tissue.

Downstream, IRR activation is associated with classic survival pathways — including JAK2/STAT and PI3K/Akt signalling — that push cells away from apoptosis (programmed cell death) and toward repair. At the same time, the pathway tempers the release of pro-inflammatory mediators such as TNF-alpha. The net research-level effect is a tissue environment that favours regeneration over scarring and chronic inflammation. Critically, none of this requires the bone marrow response that defines erythropoietin’s classic action.

Infographic text: EPO → binds two receptor types. (1) Classic EPO receptor homodimer → red blood cell production (NOT activated by ARA-290). (2) Innate repair receptor = EPO receptor + CD131 beta-common chain → tissue protection + anti-inflammatory signalling (this is the ARA-290 target). Result: repair signalling without erythropoiesis.

Key Benefits & Uses of ARA-290

Research into ARA-290 benefits has clustered around conditions where inflammation and nerve damage overlap. The reported ARA-290 benefits below reflect where investigators have focused — not proven medical uses. Outcomes in early trials should be read cautiously, and none of these uses is approved.

Neuropathic Pain and Small-Fibre Neuropathy

The most-studied application is neuropathic pain, particularly small-fibre neuropathy linked to sarcoidosis. Small randomised and open-label trials reported improvements in patient-reported pain and quality-of-life measures, alongside signals of small-fibre regeneration in some participants. These findings are encouraging but were generated in small cohorts and need larger confirmation.

Small-fibre neuropathy is notoriously difficult to manage, because the tiny unmyelinated nerves involved are hard to image and often respond poorly to standard painkillers. Researchers were drawn to cibinetide here precisely because a tissue-protective mechanism could, in theory, address the underlying nerve injury rather than just masking the pain signal. Some trial participants also reported improvements in autonomic symptoms — such as sweating and heart-rate regulation — that frequently accompany small-fibre damage, hinting at a broader nerve-protective effect that warrants further study.

Anti-Inflammatory Tissue Protection

Because IRR signalling suppresses pro-inflammatory pathways, ARA-290 has been explored for its broader tissue protection potential. Preclinical models suggest reduced inflammatory damage in nerve, kidney, and metabolic tissue. The appeal is a protective signal that does not rely on systemic immunosuppression.

Metabolic and Diabetic Neuropathy

Diabetic neuropathy is another research target. EPO-derived tissue protection is theorised to support stressed peripheral nerves, and some early metabolic-endpoint studies of cibinetide reported favourable glucose-related and inflammatory markers. Evidence here is preliminary and should not be taken as proof of benefit.

Wound Healing

Given EPO’s known role in tissue repair, the peptide has been examined for wound-healing support, especially in tissue with compromised microcirculation. Most of this work is preclinical, and human wound-healing data remain limited. The rationale is that improved cell survival and reduced local inflammation could help slow-healing wounds — for example diabetic foot ulcers — close more reliably, but this remains a hypothesis rather than an established use.

Why the Tissue-Protection Angle Matters

Across all four research areas, a single thread connects the interest: the molecule targets damage and inflammation at the cellular level instead of merely suppressing a symptom. That is rare. Most chronic-pain and anti-inflammatory tools either blunt signalling broadly or focus on one narrow target. A repair-receptor agonist that activates only on stressed tissue offers a different theoretical risk-benefit balance — one reason the compound continues to attract academic attention even though commercial development has been slow.

ARA-290 Side Effects, Safety & Dosage

In published early-phase trials, ARA-290 was generally well tolerated, with most reported effects being mild and transient. Because it does not meaningfully stimulate erythropoiesis at studied doses, it largely avoids the clotting-related concerns associated with EPO. Still, the safety database is small, and long-term data are lacking.

ARA-290 Dosage Context in Trials

The ARA-290 dosage used in research settings has typically relied on the subcutaneous (SC) route. Published sarcoidosis-neuropathy trials commonly referenced daily SC doses in the low-milligram range (for example, around 2–4 mg/day across several weeks in some protocols), often expressed relative to body weight. These figures are study reference points only — they are not a recommended human dose, and no validated dosing schedule exists outside controlled trials.

Several practical factors shaped this ARA-290 dosage approach. Subcutaneous injection gives steady absorption and is simple to self-administer in an outpatient trial. Daily dosing reflected the peptide’s relatively short circulating half-life. And researchers favoured starting low, because the goal was protective signalling rather than maximal receptor saturation. Anyone reading these numbers should remember they were chosen by clinical investigators within strict monitoring protocols — they are not transferable to unsupervised use. Reconstitution and handling matter for any laboratory peptide; see the practical guidance section below.

It is also worth flagging what is not known. There is no established maximum tolerated dose from large trials, no long-term cumulative-exposure data, and limited information on how the peptide behaves alongside common medications. Those gaps are exactly why the compound stays classified as research-grade.

What Does the Research Say?

The ARA-290 evidence base is best described as promising but early. The strongest human signals come from sarcoidosis small-fibre neuropathy work led by Dahan and colleagues. The table summarises representative findings — readers should treat all of these as preliminary.

Infographic text: ARA-290 early-trial signals (illustrative, not definitive): pain score reduction reported → small-fibre nerve markers improved in subsets → no clinically meaningful rise in red blood cell counts → tolerability favourable. Caveat: small sample sizes, short follow-up, results require larger confirmatory trials.

ARA-290 vs Alternatives

Researchers and clinicians sometimes compare ARA-290 with other approaches to nerve pain and tissue repair. The contrast below is mechanistic, not a treatment recommendation. ARA-290 differs sharply from both a regenerative peptide like BPC-157 and from symptomatic neuropathic-pain drugs like gabapentinoids.

For readers interested in the regenerative-peptide side of this comparison, our deep dive on BPC-157 for joint pain and tendon healing covers a complementary but distinct mechanism. ARA-290 sits in a different lane — protective signalling rather than direct structural repair.

How to Use ARA-290 — Practical Guidance

ARA-290 is supplied as a lyophilised (freeze-dried) powder that must be reconstituted before any laboratory use. Handling follows the same general principles as other research peptides: store the dry powder cold, reconstitute with bacteriostatic water, keep the reconstituted solution refrigerated, and avoid repeated freeze-thaw cycles. Subcutaneous administration is the route used across the published trials.

Because exact concentrations depend on vial size and the volume of solvent added, careful measurement matters. Our step-by-step walkthrough on how to reconstitute peptides explains the math, sterile technique, and storage timelines that apply to ARA-290 as well as other compounds.

You can view product specifications and current availability for ARA-290 (Cibinetide) on its product page, and browse the wider research range in our peptides category. If your interest is longevity and repair signalling more broadly, our roundup of the best longevity peptides puts ARA-290’s tissue-protective angle in context alongside related compounds.

One reminder: nothing here is dosing advice. ARA-290 is a research compound, and any human use sits outside its approved status. The figures cited from trials are reference points for understanding the literature, not instructions.

Frequently Asked Questions

What is ARA-290 used for?

In research, ARA-290 is studied for neuropathic pain — especially sarcoidosis-associated small-fibre neuropathy — as well as anti-inflammatory tissue protection, diabetic neuropathy, and wound healing. It has no approved medical indication and is supplied only as a research-grade peptide.

Does ARA-290 help nerve pain?

Early-phase human trials reported reduced neuropathic pain scores and signs of small-fibre nerve support in some participants. These results are promising but came from small cohorts with short follow-up, so they cannot be treated as proof of efficacy.

Is ARA-290 safe?

In published early trials, ARA-290 side effects were mostly mild — injection-site reactions and occasional headache. Notably, it did not meaningfully raise red blood cell counts at studied doses. However, the long-term safety database is small, and it remains investigational.

How is ARA-290 different from EPO?

EPO activates the classic erythropoietin receptor and boosts red blood cell production, which carries clotting risk. ARA-290 was designed to activate only the innate repair receptor (the EPO-receptor/CD131 heteroreceptor), aiming for tissue protection without erythropoiesis.

What is the typical ARA-290 dosage?

There is no validated human dose. Sarcoidosis-neuropathy trials referenced low-milligram daily subcutaneous doses (often around 2–4 mg/day in some protocols) over several weeks. These are study reference points only, not a recommended regimen.

How is ARA-290 administered?

Across the published studies, ARA-290 was given by subcutaneous injection after reconstitution from a lyophilised powder. Proper sterile technique, refrigerated storage, and accurate measurement are essential for any laboratory handling.

Is ARA-290 a steroid or hormone?

No. ARA-290 is a short synthetic peptide modelled on a fragment of erythropoietin. It is neither an anabolic steroid nor a conventional hormone replacement, and it does not act on androgen receptors.

Where can I learn about related peptides?

For tissue-repair comparisons, see our BPC-157 guide; for the broader repair-and-longevity picture, see our best longevity peptides roundup. Both are linked above and help place ARA-290’s mechanism in context.

The Bottom Line

ARA-290 (Cibinetide) is one of the more mechanistically elegant research peptides: by targeting the innate repair receptor, it aims to capture erythropoietin’s protective and anti-inflammatory benefits while sidestepping the red-cell increase that makes EPO risky. The most credible human evidence — in sarcoidosis small-fibre neuropathy — is genuinely encouraging, yet still early, small, and unconfirmed by large trials. That combination of strong rationale and thin confirmation is exactly why ARA-290 belongs in the research conversation rather than the medicine cabinet.

If you are exploring ARA-290 for laboratory or educational purposes, review the ARA-290 product details, learn proper handling in our reconstitution guide, and treat every dosing figure here as a reference to the literature — not as instructions for human use.

Reviewed by the MedsBase Medical Review Team. Learn how we research and verify content in our editorial policy.

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.